Transcription of バイオベンチャーの現状と課題 - METI
{{id}} {{{paragraph}}}
Example: tourism industry
バイオベンチャーの現状と課題 - METI
- . - . - . 2.. 10 .. 8PJ .. VC .. 27 471 3. M&A .. 30 6 30 17 . DATA BOOK 2017 4.. PMDA PMDA. Phase3 .. 5.. / . 1900 . ~50 . 1899 .. ~10 . 1982 .. ~10 . 2001 .. ~1000 . 1983 /Phase1 .. Exondys51 . ~10 Sarepta . DNA/RNA 2016 . Kymriah/Yescarta Kite . ~500 . 2017 Gilead . ~10 Luxturna Spark . DNA 2018 .. 6.. FDA 2016 . Active Ingredient Approval Date Approval Year . Nusinersen 12/23/2016 2016 Ionis Pharmaceuticals . Rucaparib 12/19/2016 2016 Pfizer . Crisaborole 12/14/2016 2016 Anacor Pharmaceuticals . Bezlotoxumab 10/21/2016 2016 Bristol-Myers Squibb . Olaratumab 10/19/2016 2016 ImClone Systems . Eteplirsen 9/19/2016 2016 Sarepta Therapeutics . Lixisenatide 7/27/2016 2016 Zealand Pharma . lifitegrast ophthalmic solution 7/11/2016 2016 Sunesis Pharmaceuticals . sofosbuvir and velpatasvir 6/28/2016 2016 Gilead Sciences . obeticholic acid 5/27/2016 2016 C2N Diagnostics . Daclizumab 5/27/2016 2016 PDL BioPharma.
Nusinersen 12/23/2016 2016 Ionis Pharmaceuticals ベンチャー 新薬 核酸 Rucaparib 12/19/2016 2016 Pfizer 大手 新薬 低分子 Crisaborole 12/14/2016 2016 Anacor Pharmaceuticals ベンチャー 新薬 低分子 Bezlotoxumab 10/21/2016 2016 Bristol-Myers Squibb 大手 新薬 抗体
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: